Preexposure Prophylaxis for HIV Prevention
- 1 July 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 63 (Supplement), S122-S129
- https://doi.org/10.1097/qai.0b013e3182986f69
Abstract
Preexposure prophylaxis (PrEP), in which HIV-uninfected persons with ongoing HIV risk use antiretroviral medications to reduce their risk of acquiring HIV infection, is an efficacious and promising new HIV prevention strategy. The past 2 years have seen significant new advances in knowledge regarding PrEP, including definitive demonstration that PrEP reduces the risk of HIV acquisition, regulatory approval of combination oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as the first PrEP agent with a label indication for sexual HIV prevention, and the development of normative guidance for clinical prescribing of PrEP. In PrEP clinical trials, HIV protection was strongly correlated with PrEP adherence; therefore, understanding and supporting adherence to PrEP are key to maximizing its public health impact. As would be expected for any new HIV prevention approach, questions remain, including how to motivate uptake of and sustain adherence to PrEP for HIV prevention in high-risk populations, how much use is sufficient to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve this effective prevention strategy. At this important transition point—from demonstration of efficacy in clinical trials to thinking about implementation and effectiveness—this review addresses where we have been and where we are going with PrEP for HIV prevention.Keywords
This publication has 35 references indexed in Scilit:
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant CouplesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 TransmissionScience Translational Medicine, 2011
- Pre-exposure prophylaxis for HIV prevention: how to predict successThe Lancet, 2011
- Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling StudyPLoS Medicine, 2011
- Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couplesAIDS, 2011
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with EmtricitabineJournal of Virology, 2009
- Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and TenofovirPLoS Medicine, 2008